ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2026
Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application.
Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Proteus syndrome is a rare genetic disorder characterized by progressive, abnormal overgrowth that can affect any organ or tissue in the body. This abnormality is caused by a mosaic activating variant in AKT1 that encodes a key serine/threonine kinase of the phosphoinositide-3-kinase (P13K)/AKT signaling pathway and is involved in cell growth, survival, and metabolism. Miransertib (MK-7075, formerly ARQ 092) is a novel, orally bioavailable allosteric pan-AKT inhibitor that selectively targets AKT1, AKT2, and AKT3, demonstrating potent suppression of AKT signaling and tumor growth in murine xenograft models with dysregulated signaling pathways. It has also been evaluated as a potential therapeutic option for individuals with Proteus syndrome, both in pre-clinical studies and in clinical trials. In this study, we have developed and validated a sensitive, robust, and specific LC-MS/MS method for quantifying miransertib in human plasma. The calibration curve ranged from 0.5 to 500 ng/mL in human plasma with a linearity of r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.